ArticleNature communications2026
Single-cell transcriptomics reveals FXR1 as an actionable target for siRNA therapy in ovarian cancer.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Ovarian cancer is one of the leading causes of cancer-related mortality among women and remains exceptionally difficult to manage and treat effectively in the clinic. Fragile X-related protein 1 (FXR1) is highly amplified and overexpressed in ovarian and several other cancers. FXR1 is a key regulator of the translation of multiple oncogenes and therefore represents a vulnerable target for cancer therapy. RNA interference (RNAi) of FXR1 using a locked nucleic acid (LNA) form of siRNA (siFXR1-LNA) inhibits tumor growth, ascites formation, and metastasis of ovarian cancer more efficiently than the native form of FXR1 siRNA in vivo. LNA modification of siRNA improves resistance to RNase mediated degradation and enhances tumor tissue uptake of siRNA with robust inhibition of target mRNA in tumor tissues. Single-cell RNA sequencing (scRNA-seq) analysis of ascites composed of tumor, stromal, and immune cells analysis reveals that FXR1 silencing suppresses tumor cell proliferation and reduces tumor-promoting M2-like macrophages. FXR1 silencing also increases cytotoxic T cells, NK cells, and dendritic cells with anti-tumor characteristics in vivo. Collectively, our data establishes FXR1 as an important regulator of oncogenic processes in cancer tissues and serves as a therapeutic liability. Therefore, FXR1 silencing in tumor tissues provides an effective strategy to treat tumors expressing high levels of FXR1.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.